文献速递妇科生殖医学

多囊卵巢综合征中月经紊乱严重程度与高胰岛素血症及血糖异常的关联

Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome.
PubMed 文献 · Hum Reprod · 2022-01-01

该前瞻性研究纳入333例高雄激素型多囊卵巢综合征(PCOS)女性,比较不同月经周期状态与口服葡萄糖耐量试验中高胰岛素血症及血糖异常的关系。调整BMI后,闭经组较稀发排卵或规律排卵组有更高的餐后高胰岛素血症风险,可能解释其血糖异常患病率更高。

要点

  • 闭经组较稀发排卵组血糖异常(AGT)风险更高(OR 2.3;95%CI 1.3-4.2)。
  • 闭经组较排卵规律组合并后1小时血糖升高风险更高(OR 1.8;95%CI 1.1-2.8)。
  • 闭经组较排卵规律组1小时血糖升高风险更高(OR 10.2;95%CI 1.3-79.7)。

核心结论

  • 在高雄激素型PCOS表型中,闭经史相比稀发排卵或规律排卵提示更严重的心血管代谢风险,包括更高程度的高胰岛素血症和血糖异常患病率更高。

研究设计与样本

  • 前瞻性比较333例高雄激素型PCOS女性的月经周期程度与血糖异常或动态高胰岛素血症的关系。

主要发现

  • 调整BMI后,闭经组平均1小时和2小时胰岛素及血糖、峰值胰岛素、胰岛素曲线下面积(I-AUC)和血糖曲线下面积(G-AUC)均高于稀发排卵组、无排卵规律排卵组或有排卵规律排卵组。
  • 调整BMI的logistic回归中,闭经组较稀发排卵组血糖异常(AGT)风险更高(OR 2.3;95%CI 1.3-4.2)。
  • 闭经组较有排卵规律排卵组1小时血糖升高风险更高(OR 10.2;95%CI 1.3-79.7)。
  • 闭经组较无排卵规律排卵组和有排卵规律排卵组合并后血糖异常(AGT)风险更高(OR 1.7;95%CI 1.1-2.6),1小时血糖升高风险亦更高(OR 1.8;95%CI 1.1-2.8)。

关键数值与推荐

  • 血糖异常定义为1小时血浆葡萄糖≥155 mg/dl,包括糖尿病前期和2型糖尿病。
  • 动态高胰岛素血症定义为口服葡萄糖耐量试验1小时或2小时峰值胰岛素水平及胰岛素曲线下面积(I-AUC)。

局限性

  • 研究为横断面性质。
  • 研究对象为根据Androgen Excess & PCOS Society标准定义的PCOS女性(即Rotterdam表型A、B和C),且在临床环境中识别。
  • 将本研究数据外推至其他PCOS表型(如PCOS表型D)应谨慎。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Is the severity of menstrual cyclicity related to hyperinsulinemia and dysglycemia in women with hyperandrogenic polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Hyperandrogenic PCOS women with amenorrhea, compared to those with oligomenorrhea or eumenorrhea, had a greater risk of post-challenge hyperinsulinemia, which may explain their higher prevalence of dysglycemia. WHAT IS KNOWN ALREADY: PCOS is associated with metabolic dysregulation including insulin resistance (IR) and hyperinsulinemia, risk factors for type 2 diabetes mellitus (T2DM) and other vascular-metabolic morbidities. Although the severity of menstrual cyclicity is associated with IR in PCOS, it is unclear whether, and to what extent, it is related to hyperinsulinemia and glycemic abnormalities. STUDY DESIGN, SIZE, DURATION: We prospectively compared the degree of menstrual cyclicity with the presence of dysglycemia (elevated 1-h plasma glucose ≥155 mg/dl; abnormal glucose tolerance [AGT], including prediabetes and T2DM; and AUC for glucose [G-AUC]) or dynamic state hyperinsulinemia (peak insulin levels either at 1 or 2 h of the oral glucose tolerance test (oGTT) and AUC for insulin [I-AUC]) in 333 hyperandrogenic PCOS women. PARTICIPANTS/MATERIALS, SETTING, METHODS: In a tertiary care setting, hyperandrogenic PCOS participants with ovulatory eumenorrhea (Ov-Eumeno, n = 25), anovulatory eumenorrhea (Anov-Eumeno, n = 33), oligomenorrhea (Oligo, n = 150) and amenorrhea (Ameno, n = 125) underwent comprehensive phenotyping and a 2-h 75 g oGTT. MAIN RESULTS AND THE ROLE OF CHANCE: Mean BMI was greater among Ameno women than among Oligo, Anov-Eumeno or Ov-Eumeno women. Adjusting for BMI, the Ameno group demonstrated higher mean 1- and 2-h insulin and glucose, peak insulin and I-AUC and G-AUC, and either had a higher, or tended toward having a higher, prevalence of elevated 1-h glucose level and prevalence of AGT than the Oligo, Anov-Eumeno or Ov-Eumeno groups. In logistic regression, adjusting for BMI, Ameno women were more likely to have: AGT than Oligo women (odds ratio [OR]: 2.3; 95% CI: 1.3 to 4.2); elevated 1-h glucose (OR: 10.2; CI: 1.3-79.7) than those with Ov-Eumeno; and both AGT (OR: 1.7; CI: 1.1-2.6) and elevated 1-h glucose (OR: 1.8; CI: 1.1-2.8) than those with Anov-Eumeno or Ov-Eumeno when combined. Race/ethnicity, age, waist-to-hip ratio, fasting insulin and glucose, and biochemical or clinical measures of hyperandrogenism were similar across the four menstrual categories. LIMITATIONS, REASONS FOR CAUTION: Our study was limited by its cross-sectional nature and by studying women affected by PCOS as defined by the Androgen Excess & PCOS Society criteria (i.e. Rotterdam Phenotypes A, B and C) who were identified in the clinical setting. Consequently, extrapolation of the present data to other PCOS phenotypes (e.g. PCOS Phenotype D) should be made with caution. WIDER IMPLICATIONS OF THE FINDINGS: In hyperandrogenic PCOS phenotypes, a history of amenorrhea, compared to oligomenorrhea or eumenorrhea, suggests a more severe cardiometabolic risk, including a higher degree of hyperinsulinemia and greater prevalence of glycemic abnormalities. These findings may assist in refining the treatment and screening guidelines for glycemic abnormalities in PCOS. STUDY FUNDING/COMPETING INTEREST(S): This work was supported in part by grants R01-DK073632 and R01-HD29364 from the NIH and an endowment of the Helping Hand of Los Angeles, Inc. (to R.A.). M.D.P. has no competing interests to declare. U.E. is an investor in Concentric Analgesics, Inc. R.A. serves as a consultant for Spruce Biosciences and Fortress Biotech and an advisor for Aurora Forge. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Ezeh U, Pisarska MD, Azziz R, et al. Association of severity of menstrual dysfunction with hyperinsulinemia and dysglycemia in polycystic ovary syndrome. Hum Reprod. 2022. PMID: 35048126. doi:10.1093/humrep/deac001

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。